Peer-reviewedLicence not statedThe Journal of rheumatology
PATIENT-REPORTED OUTCOMES FOLLOWING DISCONTINUATION OF TUMOR NECROSIS FACTOR INHIBITORS IN RHEUMATOID ARTHRITIS REMISSION/LOW DISEASE ACTIVITY: A RANDOMIZED PLACEBO-CONTROLLED TRIAL
11 affiliations
- 1Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda MD.
- 2Department of Medicine, Medstar Washington Hospital Center, Washington DC.
- 3Arthritis and Rheumatism Associates, Wheaton MD.
- 4Arthritis and Pain Associates of PG County, Greenbelt MD.
- 5Arthritis and Rheumatic Disease Associates, Burke, VA.
- 6Washington DC Veterans Affairs Medical Center, Washington DC, Georgetown and Howard University Hospitals, Uniformed Services University of the Health Sciences, Washington DC.
- 7Department of Medicine, University of Maryland Medical Center, Baltimore MD.
- 8Arthritis Clinic of Northern Virginia, Arlington VA.
- 9Department of Internal Medicine, Virginia Commonwealth University, Richmond VA.
- 10Arthritis and Osteoporosis Center of Northern Virginia, Manassas VA.
- 11Geisinger Health System, Danville, PA.
Related
- Durability of Semaglutide Effects After Treatment Discontinuation in HIV-Associated Lipohypertrophy: A Randomized, Double-Blind, Placebo-Controlled Phase 2b Clinical Trial.
- Disease-modifying therapies (DMTs) discontinuation in older relapsing-remitting multiple sclerosis (RRMS) patients with stable disease: Two-year randomized, controlled trial.
- PARP inhibitors and newly second primary malignancies in cancer patients: a systematic review and safety meta-analysis of placebo randomized controlled trials
- Effect of proactive therapeutic drug monitoring on maintenance of sustained disease control in adults with rheumatoid arthritis on a subcutaneous TNF inhibitor: the Rheumatoid Arthritis therapeutic DRUg Monitoring trial (RA-DRUM)—study protocol for a phase IV randomized controlled trial
- Long‐Term Neurodevelopmental Outcome Following Three Randomized Controlled Trials of Choline in Fetal Alcohol Spectrum Disorder (FASD)
BibTeX
@article{ward2026patientreported,
title = {{PATIENT-REPORTED OUTCOMES FOLLOWING DISCONTINUATION OF TUMOR NECROSIS FACTOR INHIBITORS IN RHEUMATOID ARTHRITIS REMISSION/LOW DISEASE ACTIVITY: A RANDOMIZED PLACEBO-CONTROLLED TRIAL}},
author = {Michael M. Ward and Arthur Weinstein and Paloma Alejandro-Silva and Alan K. Matsumoto and Rukmini M. Konatalapalli and Neil Stahl and Gail S. Kerr and Jamal Mikdashi and Phillip W. Kempf and Nehal R. Shah and Stamatina Danielides and Moshen Ghafouri and Thomas P. Olenginski and Alice Fike and Florina Constantinescu},
journal = {The Journal of rheumatology},
year = {2026},
month = oct,
doi = {10.3899/jrheum.2026-0356},
url = {https://doi.org/10.3899/jrheum.2026-0356},
}
RIS
TY - JOUR
TI - PATIENT-REPORTED OUTCOMES FOLLOWING DISCONTINUATION OF TUMOR NECROSIS FACTOR INHIBITORS IN RHEUMATOID ARTHRITIS REMISSION/LOW DISEASE ACTIVITY: A RANDOMIZED PLACEBO-CONTROLLED TRIAL
AU - Michael M. Ward
AU - Arthur Weinstein
AU - Paloma Alejandro-Silva
AU - Alan K. Matsumoto
AU - Rukmini M. Konatalapalli
AU - Neil Stahl
AU - Gail S. Kerr
AU - Jamal Mikdashi
AU - Phillip W. Kempf
AU - Nehal R. Shah
AU - Stamatina Danielides
AU - Moshen Ghafouri
AU - Thomas P. Olenginski
AU - Alice Fike
AU - Florina Constantinescu
PY - 2026
DA - 2026/10/15
JO - The Journal of rheumatology
DO - 10.3899/jrheum.2026-0356
UR - https://doi.org/10.3899/jrheum.2026-0356
SN - 0315-162X
SN - 1499-2752
ER -